EDAP TMS (EDAP) announced that the French Ministry of Health has awarded reimbursement for High Intensity Focused Ultrasound procedure for the treatment of prostate cancer in France. Reimbursement in France will specifically cover use of the Focal One Robotic HIFU procedure for eligible patients as a primary treatment of localized prostate cancer as well as a salvage treatment option following radiotherapy.T his final step in the reimbursement pathway follows the positive favorable opinion issued in December 2023 by the French National Authority for Health to include HIFU as a procedure covered under the national universal health system, Social Security following the completion and analysis of the HIFI Study sponsored by the French Urology Association. Coverage became effective on September 1, 2025, and reimbursement details will become available in the near future.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDAP:
- Promising Growth Trajectory and Strategic Moves Justify Buy Rating for EDAP TMS
- EDAP TMS S.A. Reports Strong HIFU Growth Amid Challenges
- EDAP TMS S.A. Reports Strong Q2 2025 HIFU Growth
- EDAP TMS Reports Record Q2 2025 HIFU Growth and Strategic Expansion Plans
- EDAP TMS reports Q2 EPS (17c) vs (18c) last year